IP Library Granted Patent US 10,907,175
Granted Patent B2
US 10,907,175 · App. 14/947,476 · Granted Feb 2, 2021

Isolated human cell with an inactivated glucocorticoid receptor gene

Inventors: Andreas Reik (Vallejo, CA); Michael Jensen (Sierra Madre, CA); Michael C. Holmes (Oakland, CA); Philip D. Gregory (Orinda, CA); Dale Ando (Walnut Creek, CA)
Assignees: Sangamo Therapeutics, Inc.; City of Hope
C12N15/86C07K14/721C12N9/22C12N15/62G01N33/743C12N2710/10043C12N2740/15043G01N2333/723
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,907,175
App. No.
14/947,476
Granted
Feb 2, 2021
Kind
B2
Abstract

Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.

Claims (17)

1. An isolated human cell with an inactivated human glucocorticoid receptor (GR) gene, the isolated human cell comprising:

(i) a first zinc finger nuclease (ZFN) comprising a zinc finger DNA-binding domain comprising the following recognition helices in the following order:

TSRALTA (SEQ ID NO: 23);

DRANLSR (SEQ ID NO: 17);

RSDNLSE (SEQ ID NO: 24);

ERANRNS (SEQ ID NO:26); and

(ii) a second zinc finger nuclease (ZFN) comprising a zinc finger DNA-binding domain comprising the following recognition helices in the following order:

DSWNLQV (SEQ ID NO:33);

RSANLTR (SEQ ID NO: 27);

TSGNLTR (SEQ ID NO:30);

TSGSLTR (SEQ ID NO:31).

2. The isolated human cell of claim 1 comprising one or more polynucleotides encoding the first and second ZFNs.

3. The isolated human cell of claim 2 , wherein an expression vector comprises the one or more polynucleotides.

4. The isolated human cell of claim 3 , wherein the expression vector is a viral delivery vector.

5. The isolated human cell of claim 4 , wherein the viral delivery vector is an adenovirus, a hybrid adenovirus or a non-integrating lentivirus.

6. A method of making an isolated human hematopoietic cell or T-cell with a cleaved GR gene, the method comprising contacting an isolated human hematopoietic or T-cell cell with the one or more polynucleotides of claim 2 such that the endogenous GR gene is cleaved and inactivated.

7. The isolated human cell of claim 1 , wherein the cell is a T-cell or a hematopoietic cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2023
From: REIK, ANDREAS; HOLMES, MICHAEL C.; GREGORY, PHILIP D.; ANDO, DALE
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 064565/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2023
From: JENSEN, MICHAEL
To: CITY OF HOPE
Reel/Frame 064565/0305 →
CHANGE OF NAME Recorded Oct 9, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 054039/0995 →
Continuity (5)
Continuation 11983888 · Nov 13, 2007
Provisional Application 60859025 · Nov 13, 2006
Provisional Application 60859417 · Nov 15, 2006
Provisional Application 60967820 · Sep 7, 2007
Related Publication 20160076056A1 · Mar 17, 2016